ArticleLancet (London, England)2022
WHO's Therapeutics and COVID-19 Living Guideline on mAbs needs to be reassessed.
Abstract readLetter
In one paragraph
Article in Lancet (London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.The Lancet. Infectious diseases · 2026Trial
- Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration.Nature communications · 2023Trial
- Article
- A cocktail of SARS-CoV-2 S stem helix domain and receptor binding domain human monoclonal antibodies prevents the emergence of viral escape mutants.Microbiology spectrum · 2026Article
- Drug-resistant tuberculosis and pulmonary co-infections in immunocompromised patients: from multi-omics to precision therapy.Frontiers in microbiology · 2026Review
- A cocktail of SARS-CoV-2 spike stem helix domain and receptor binding domain human monoclonal antibodies prevent the emerge of viral escape mutants.bioRxiv : the preprint server for biology · 2025Article
- A luminescent attenuated SARS-CoV-2 for the identification and validation of drug-resistant mutants.Journal of virology · 2025Article
- Organoid-based neutralization assays reveal a distinctive profile of SARS-CoV-2 antibodies and recapitulate the real-world efficacy.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Improved Resolution of Influenza Vaccination Responses With High-Throughput Live Virus Microneutralisation.Influenza and other respiratory viruses · 2025Article
- Corticosteroids in immunocompromised ICU patients with severe COVID-19: a multicenter retrospective study.Scientific reports · 2025Article
- Monoclonal Antibody Therapies Against SARS-CoV-2: Promises and Realities.Current topics in microbiology and immunology · 2025Review
- An Overview of the Strategies to Boost SARS-CoV-2-Specific Immunity in People with Inborn Errors of Immunity.Vaccines · 2024Review
- COVID-19 therapeutics.Clinical microbiology reviews · 2024Review
- SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs.Cell chemical biology · 2024Review
- Divergent performance of vaccines in the UK autumn 2023 COVID-19 booster campaign.Lancet (London, England) · 2024Article
- Article
- Article
- A Multinational Case Series Describing Successful Treatment of Persistent Severe Acute Respiratory Syndrome Coronavirus 2 Infection Caused by Omicron Sublineages With Prolonged Courses of Nirmatrelvir/Ritonavir.Open forum infectious diseases · 2024Article
- Comparative effectiveness of nirmatrelvir/ritonavir versus sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in non-hospitalised high-risk patients during Omicron waves: observational cohort study using the OpenSAFELY platform.The Lancet regional health. Europe · 2023Article
- Comparative effectiveness of sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in patients on kidney replacement therapy: observational study using the OpenSAFELY-UKRR and SRR databases.Clinical kidney journal · 2023Article
Corrections and comments
- Commented on by
Authors and funding
19 authors.
Mary Y WuThe Francis Crick Institute, London NW1 1AT, UK.
Edward J CarrThe Francis Crick Institute, London NW1 1AT, UK.
Ruth HarveyWorldwide Influenza Centre, The Francis Crick Institute, London, UK.
Harriet V MearsThe Francis Crick Institute, London NW1 1AT, UK.
Svend KjaerThe Francis Crick Institute, London NW1 1AT, UK.
Hermaleigh TownsleyThe Francis Crick Institute, London NW1 1AT, UK; Worldwide Influenza Centre, The Francis Crick Institute, London, UK.
Agnieszka HobbsThe Francis Crick Institute, London NW1 1AT, UK.
Martina RagnoThe Francis Crick Institute, London NW1 1AT, UK.
Lou S HermanThe Francis Crick Institute, London NW1 1AT, UK.
Lorin AdamsWorldwide Influenza Centre, The Francis Crick Institute, London, UK.
Steve GamblinThe Francis Crick Institute, London NW1 1AT, UK.
Michael HowellThe Francis Crick Institute, London NW1 1AT, UK.
Rupert BealeThe Francis Crick Institute, London NW1 1AT, UK.
Michael BrownNational Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre and NIHR UCLH Clinical Research Facility, London, UK.
Bryan WilliamsNational Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre and NIHR UCLH Clinical Research Facility, London, UK; University College London, London, UK.
Sonia GandhiThe Francis Crick Institute, London NW1 1AT, UK; University College London, London, UK.
Charles SwantonThe Francis Crick Institute, London NW1 1AT, UK; University College London, London, UK.
Emma C WallThe Francis Crick Institute, London NW1 1AT, UK; National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre and NIHR UCLH Clinical Research Facility, London, UK.
David L V BauerThe Francis Crick Institute, London NW1 1AT, UK. Electronic address: david.bauer@crick.ac.uk.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
COVID-19HumansWorld Health Organization
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.